Shedding light

on blood flow  

Shedding light

on blood flow  

Shedding light

on blood flow

We develop a microfluidic-based platform to advance hematological diagnostics, assist therapy decision-making and improve patient safety.

Our technology enables a high-throughput, AI-powered assessment of the morphology and functionality of blood on a cellular level.

Technology

Over 25 trillion red blood cells travel through our bodies every minute. Their shape is a highly sensitive parameter for both intrinsic cell properties and external influences. Erysense utilizes red blood cell shape features as a biomarker.
Schematic shapes of red blood cells in flow
Microscopy images of cells recorded by Erysense
The Erysense platform simulates microvascular blood flow in microchannels with a diameter 10X smaller than a human hair. Using an automated AI-based cell shape evaluation, Erysense constitutes a fast and robust point-of-care system for patient-centered assessment of blood functionality.

Technology

Over 25 trillion red blood cells travel through our bodies every minute. Their shape is a highly sensitive parameter for both intrinsic cell properties and external influences. Erysense utilizes red blood cell shape features as a biomarker.

Schematic shapes of red blood cells in flow
Microscopy images of cells recorded by Erysense
The Erysense platform simulates microvascular blood flow in microchannels with a diameter 10X smaller than a human hair. Using an automated AI-based cell shape evaluation, Erysense constitutes a fast and robust point-of-care system for patient-centered assessment of blood functionality.

Advantages

Small sample volume

Erysense requires only one drop of blood, avoiding the need of specialized personnel for sampling and minimizing patient blood loss.

Analysis on a single-cell level

The shape of red blood cells is highly influenced by the intrinsic cell properties and external conditions. Erysense enables the examination of such effects on the morphology of individual cells at high-throughput.

Versatility

Erysense enables advanced hematological diagnosis, individualized therapy, and in-vitro drug testing.

Advantages

Small sample volume

Erysense requires only one drop of blood, avoiding the need of specialized personnel for sampling and minimizing patient blood loss.

Analysis on a single-cell level

The shape of red blood cells is highly influenced by the intrinsic cell properties and external conditions. Erysense enables the examination of such effects on the morphology of individual cells at high-throughput.

Versatility

Erysense enables advanced hematological diagnosis, individualized therapy, and in-vitro drug testing.

Applications

Blood quality assessment for transfusion medicine

Advanced hematological diagnostics

Blood and cell
research
 

In-vitro testing for drug development

Biomedical technologies, e.g., cell-based drug delivery

Blood quality
assessment for
transfusion
medicine

Advanced
hematological
diagnostics
 
 
Blood and cell
research
 
In-vitro
testing for drug
development
 
Biomedical
technologies, e.g.,
cell-based
drug delivery

Meet our team

Our interdisciplinary team combines scientific excellence in red blood cell research with expertise in microfluidics, cell biology, microscopy, and AI.

This diversified background motivates us to unify our strengths for a mutual goal: setting new standards in hematology with our Erysense Technology.

Advisory Board

read more...

Dr. Martin Gitzinger

Q

Dr. Martin Gitzinger

Dr. Gitzinger joined Cysmic in the year 2021 as shareholder and legal advisor.
Before that he was and continues to be a business lawyer for nearly 30 years with a wide experience in intellectual property law.
As a student, he worked on an rule based expert system on the UN Sales Law and earned his doctorate in computational logics and linguistics.
Dr. Gitzinger was one of the first shareholders of Pyrum Innovations AG, a green technology start up that recycles tires through a pyrolysis process in oil, gas and carbon black. He played an instrumental role in initiating the investors process and building a corporate culture. Pyrum was going public in 2021.
Today, he leads the development of corporate compliance and certification at Cysmic.The Erysense platform simulates microvascular blood flow in microchannels with a diameter 10X smaller than a human hair. Using an automated AI-based cell shape evaluation, Erysense constitutes a fast and robust point-of-care system for patient-centered assessment of blood functionality.

LinkedIn

Dr. Martin Gitzinger

Q

Dr. Martin Gitzinger

Dr. Gitzinger joined Cysmic in the year 2021 as shareholder and legal advisor.
Before that he was and continues to be a business lawyer for nearly 30 years with a wide experience in intellectual property law.
As a student, he worked on an rule based expert system on the UN Sales Law and earned his doctorate in computational logics and linguistics.
Dr. Gitzinger was one of the first shareholders of Pyrum Innovations AG, a green technology start up that recycles tires through a pyrolysis process in oil, gas and carbon black. He played an instrumental role in initiating the investors process and building a corporate culture. Pyrum was going public in 2021.
Today, he leads the development of corporate compliance and certification at Cysmic.The Erysense platform simulates microvascular blood flow in microchannels with a diameter 10X smaller than a human hair. Using an automated AI-based cell shape evaluation, Erysense constitutes a fast and robust point-of-care system for patient-centered assessment of blood functionality.

LinkedIn

Patrick Klein

Sebastian Rohde

Contact

+49 176 3078 4328

info(at)cysmic.de

Universität des Saarlandes
Starterzentrum A1 2
66123 Saarbrücken

contact us!